Skip to content
value.today

GoodRx: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, 1.3% a year (statements).

%

US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt less cash at the end of FY2025 (statements); negative means more cash than debt.

What today's price assumes

A market value of $1.2 B means free cash flow growing -3.5% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.

Revenue grew 1.3% a year over the last three years.

Cash-flow value of the shares
$1.8 B
+49% against the market value
Value of the whole business
$2.0 B
before net debt
Value from after year 10
47%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →-3.7%-1.2%1.3%3.8%6.3%
8.15%+35%+67%+107%+155%+214%
9.15%+14%+41%+74%+113%+161%
10.15%-1%+21%+49%+82%+122%
11.15%-13%+6%+30%+58%+92%
12.15%-23%-6%+15%+39%+69%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

Price to salesPrice to sales of Healthcare Information Services: $932 M to $5.4 B, median $1.5 BPrice to bookPrice to book of Healthcare Information Services: $733 M to $3.0 B, median $1.3 BCash-flow value$0 M$1.5 B$2.9 B$4.4 B$5.8 BMarket value $1.2 B

Your own DCF model

A full discounted-cash-flow model of GoodRx, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Healthcare Information Services

Multiples of its companies with a market value at most 60 days old, times GoodRx's own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)GoodRxApplied toValue (25th to 75th)Companies
Price to sales1.2× / 1.9× / 6.8×1.5×revenue $797 M$932 M to $5.4 B14
Price to book1.2× / 2.2× / 4.9×1.9×book equity $616 M$733 M to $3.0 B14

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

GoodRx's multiples at each month end with a market cap on file, Jan 2021 to Oct 2026, each against its own median.

Price to sales

1.5×

Now below its median of 2.6×, in the bottom quarter of its range; range 1.0× to 40.7× over 8 months.

0×10×20×31×41×202120222023202420252026Price to sales 2×Median 3×

Price to book

1.9×

Now below its median of 2.2×, in the bottom quarter of its range; range 1.3× to 14.8× over 7 months.

0×4×7×11×15×2023202420252026Price to book 2×Median 2×

as of Oct 14, 2026. Market caps: the dated values on file since 2020. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 14, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$797 M$30 M$168 M$4 M$164 M$233 MSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$792 M$16 M$184 M$1 M$183 M$52 MSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$750 M$-9 M$138 M$1 M$137 M$-25 MSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$767 M$-33 M$147 M$4 M$143 M$-90 MSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$745 M$-25 M$179 M$5 M$174 M$-267 MSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$551 M$-294 M$131 M$21 M$111 M$-288 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $1.2 B on Oct 14, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.